Effect of Exercise Training Under HFO Device on Endurance Tolerance in Patients With COPD and CRF: a Randomized Controlled Study.
Launched by ISTITUTI CLINICI SCIENTIFICI MAUGERI SPA · Oct 23, 2017
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
160 patients will be enrolled in 4 different hospitals. One of those, ICS Maugeri, will contribute with 5 different Institutes \[Brescia, Pavia, Tradate (VA),Veruno (NO) and Cassano delle Murge (BA)\]. Thus the total recruiting centers will be eight.
During the whole rehabilitation period, the patients will perform one training session/day.
The patients will use medications and oxygen therapy at rest as prescribed. The patients will perform no less than 20 training sessions within a period of one month. The rehabilitative intervention will be constantly supervised by a respiratory therapi...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • COPD and CRF diagnosis under LTOT,
- • clinical stability (pH \> 7.35 and \< 7.46, no change in respiratory drugs therapy during the last seven days)
- Exclusion Criteria:
- • orthopedic or neurological disease,
- • cognitive impairment (Mini Mental State Examination \< 22)
- • anamnestic history of ischemic heart disease or heart failure, COPD+ fibrosis and COPD+ OSAS.
About Istituti Clinici Scientifici Maugeri Spa
Istituti Clinici Scientifici Maugeri S.p.A. is a prestigious Italian healthcare organization dedicated to advancing medical research and clinical practice. With a strong focus on patient-centered care, the institution integrates innovative clinical trials into its comprehensive services, fostering collaboration between researchers and healthcare professionals. Known for its commitment to high-quality standards and ethical practices, Istituti Clinici Scientifici Maugeri S.p.A. plays a pivotal role in the development of new therapies and treatment modalities, contributing significantly to the global medical community and enhancing patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lumezzane, Brescia, Italy
Patients applied
Trial Officials
Michele Vitacca, MD
Principal Investigator
ICS Maugeri Lumezzane
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials